Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Stock Information for Benitec Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Benitec Biopharma Inc.

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
Benitec Biopharma Inc. Announces Proposed Public Offering
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Benitec Biopharma Provides Operational Updates
Benitec Biopharma Releases Third Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.